PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

2000 4767-0 (ref only)

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 403/14, A61K 31/40

A1

(11) International Publication Number: WO 99/47518

(43) International Publication Date: 23 September 1999 (23.09.99)

(21) International Application Number: PCT/EP99/01534

(22) International Filing Date: 10 March 1999 (10.03.99)

(30) Priority Data:
60/078,331 17 March 1998 (17.03.98) US

(71) Applicant: F. HOFFMANN–LA ROCHE AG [CH/CH]; 124 Grenzacherstrasse, CH–4070 Basel (CH).


(72) Inventors: DHINGRA, Urvashi, Hooda; 82 Beech Street, Nutley, NJ 07110 (US). HURYN, Donna, Mary; 8 Tyler Court, Allentown, NJ 08501 (US). KE, June; 5 Carlton Drive, Montclair, NJ 07043 (US). WEBER, Giuseppe, Federico; 192 Anderson Parkway, Cedar Grove, NJ 07009 (US).

(74) Agent: MEZGER, Wolfgang; 124 Grenzacherstrasse, CH–4070 Basel (CH).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SUBSTITUTED BISINDOLYMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION



(I)

(57) Abstract

Substituted pyrroles of formula (I) wherein R^1 is hydrogen and R^2 is methyl or R^1 is methyl and R^2 is hydrogen or R^1 is hydroxymethyl and R^2 is methyl as well as pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts thereof are antiproliferative agents useful in the treatment of cancer.